ESMO: Tumor Shrinkage Doesn't Predict Response to Imatinib Therapy in Patients With Gastrointestinal Stromal Tumors
|Posted by Administrator (admin) on Mar 13 2006|
|GIST In the News >>|
By Charlene Laino
AUSTRIA -- November 4, 2004 -- Lack of progression is the most
clinically significant predictor of a patient's response to imatinib in
patients with gastrointestinal stromal tumours (GIST), a new analysis
clinicians traditionally use tumour shrinkage to assess the anticancer
activity of a given therapy, the new study suggests that, at least in
this instance, the paradigm does not fit, said co-investigator Stan N.
Finkelstein, MD, a senior research scientist at Massachusetts Institute
of Technology Sloan School of Management in Cambridge, Massachusetts,
"If you have a patient with GIST on imatinib and the disease is not progressing, it is worth keeping therapy up -- even if you don't see tumour shrinkage on radiological scans," Dr. Finkelstein said. "Patients with so-called stable disease do just as well as those who have a partial or complete response."
Full Text at: http://www.pslgroup.com/dg/247876.htm
Last changed: Mar 13 2006 at 11:52 AMBack